DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Brilacidin
Brilacidin
Brilacidin First-In-Class Defensin-Mimetic Drug Candidate
Current Topics in Medicinal Chemistry, 2017, 17, 576-589
Advances in Antibiotic Therapy in the Critically Ill Jean-Louis Vincent1*, Matteo Bassetti2, Bruno François3, George Karam4, Jean Chastre5, Antoni Torres6, Jason A
Antibiotics Currently in Clinical Development
Antibiotic Update
Brilacidin Demonstrates Inhibition of SARS-Cov-2 in Cell Culture
Recent Advances in the Development of Antibacterial Agents
Self-Assembling Dipeptide Antibacterial Nanostructures with Membrane Disrupting Activity
(12) Patent Application Publication (10) Pub. No.: US 2016/0243117 A1 MENON (43) Pub
S. Aureus and MDR CNS DAP and DAP MSSA and MRSA Proteins Recently Completed a Phase 2 Clinical Trial for Treatment of Staphylococcus- Associated ABSSSI
Recent Advances in Design of Antimicrobial Peptides and Polypeptides Toward Clinical Translation
Antibiotic-Loaded Polymeric Microspheres for Passive Lung Targeting After Intravenous Administration
Antimicrobial Lipopeptide Tridecaptin A1 Selectively Binds to Gram-Negative Lipid II
Brilacidin, Host Defence Peptide Mimetic, One of a New Class of Immunomodulatory Agents That Can Target Multiple Disease Indications
Antibiotic Adjuvants Â
The Multifaceted Nature of Antimicrobial Peptides: Current Synthetic Chemistry Approaches and Cite This: Chem
Novel Antibiotics Effective Against Gram-Positive and -Negative Multi
The Road from Host-Defense Peptides to a New Generation of Antimicrobial Drugs
Top View
2019 Antibacterial Agents in Clinical Development
Bacterial Targets of Antibiotics in Methicillin-Resistant Staphylococcus Aureus
Brilacidin First-In-Class Defensin-Mimetic Drug Candidate Background and Scientific Rationale for Brilacidin As a Potential Novel Coronavirus (COVID-19) Treatment
Brilacidin-In-Ulcerative
Antibiotics in the Clinical Pipeline in October 2019
Bacteremia Due to Methicillin-Resistant Staphylococcus Aureus New Therapeutic Approaches
Literature Search Strategy for Treatment of Stable
Clinical Decision Support Systems to Improve Antibiotic Use in Hospitals Antibiotic Stewardship Clinical Decision Support
20 Progress—Development of New Drugs Active Against Gram-Negative Bacilli: an Update from the Infectious Diseases Society of America
Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent in Vitro Antiviral Activity Against SARS-Cov-2
De-Risking Antibiotic Drug Development with PK-PD
BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
A Scientific Roadmap for Antibiotic Discovery
Recent Progress in the Development of Small-Molecule Ftsz Inhibitors As Chemical Tools for the Development of Novel Antibiotics
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
ESCMID Elibrary © by Author
New Antimicrobials Brilacidin, Host Defence Peptide Mimetic, One of a New Class of Immunomodulatory Agents That Can Target Multiple Disease Indications
The Continuing Threat of Methicillin-Resistant Staphylococcus Aureus
The Clinical Potential of Antimicrobial Peptides
Methicillin-Resistant Staphylococcus Aureus: Prevention and Treatment 2 Contact Hours
ANTIBACTERIAL AGENTS in CLINICAL DEVELOPMENT an Analysis of the Antibacterial Clinical Development Pipeline, Including Tuberculosis
Ceftazidime/Avibactam Allergan/Pfizer Approved February 25, 2015 EMA: June 2016 6
Antibiotics in the Clinical Pipeline in 2013
Development of Novel Antimicrobial Peptides with Improved Hemocompatibility
Antimicrobial Resistance in the 21St Century, Emerging Infectious Diseases of the 21St Century, 756 Index
Antimicrobial Activity and Mode of Action of Bacteriocin AS-48 Against Mycobacterium Tuberculosis